


AMENDMENTS TO THE CLAIMS

Please amend this application as described in the Listing of Claims, which will replace all prior versions and listings of claims in the above-referenced application.

LISTING OF CLAIMS


1-18. (Canceled)

19. (Currently amended) An oxycodone prodrug of claim 16 having the structure




or a pharmaceutically acceptable salt thereof.

20. (Original) An oxycodone prodrug having the structure




or a pharmaceutically acceptable salt thereof.

21. (Currently amended) An oxycodone prodrug of claim 16 having the structure




or a pharmaceutically acceptable salt thereof.

22. (Original) An oxycodone prodrug having the structure



or a pharmaceutically acceptable salt thereof.


23. (Currently amended) An oxycodone prodrug of claim 16 having the structure



wherein, R_1 , selected from the group consisting of:


- a. hydrogen;
- b. C_{1-4} alkyl unsubstituted or substituted with CH_3 or C_{3-7} cycloalkyl, or amino or guanidino or amidino or carboxy or acetamido or carbamyl or sulfonate, or phosphate or phosphonate;
- c. C_{1-4} alkoxy;
- d. methylenedioxy;
- e. hydroxy;
- f. carboxy;
- g. sulfonate;
- h. C_{3-7} cycloalkyl;
- i. aryl, unsubstituted or substituted with guanidino, amidino, carboxy, acetamido, carbamyl, sulfonate, phosphate, or phosphonate;
- j. benzyl, unsubstituted or substituted with guanidino, amidino, carboxy, acetamido, carbamyl, sulfonate, phosphate, or phosphonate; and
- k. (a) to (j) with additional carbon groups to form a C_{3-7} cycloalkyl ring,
 or a pharmaceutically acceptable salt thereof.

24. (Currently amended) An oxycodone prodrug having the structure




wherein R_1 is defined as in claim 23, or a pharmaceutically acceptable salt thereof.

25. (Currently amended) An oxycodone prodrug of claim 16 having the structure




or a pharmaceutically acceptable salt thereof.

26. (Original) An oxycodone prodrug having the structure




or a pharmaceutically acceptable salt thereof.

27. (Currently amended) An oxycodone prodrug of claim 16 having the following structure




wherein R₁ and R₂ are defined as is R₁ in claim 23, or a pharmaceutically acceptable salt thereof.

28. (Currently amended) An oxycodone prodrug of claim 16 having the following structure




wherein R₁ and R₂ are defined as is R₁ in claim 23, or a pharmaceutically acceptable salt thereof.

29. An oxycodone prodrug of claim 16 having the following structure




wherein Y is independently selected from the group consisting of:



wherein the values of u and v are independently selected from the values 0, 1, 2 or 3, and wherein R₁ and R₂ are defined as is R₁ in claim 23, and wherein R₄ is independently selected a C₁₋₄ alkyl acyl group unsubstituted or substituted with CH₃ or C₃₋₇ cycloalkyl, amino, guanidino, amidino, carboxy, acetamido, carbamyl, sulfonate, phosphate, or phosphonate.


or a pharmaceutically acceptable salt thereof.

30. (Currently amended) An oxycodone prodrug of claim 16 having the following structure




or a pharmaceutically acceptable salt thereof.

31. (Currently amended) An oxycodone prodrug of claim 16 having the following structure




or a pharmaceutically acceptable salt thereof.

32. (Currently amended) An oxycodone prodrug of claim 16 having the following structure




wherein R_1 is defined as in claim 23, or a pharmaceutically acceptable salt thereof.

33. (Currently amended) A compound of claim 16 An oxycodone prodrug having the following structure



wherein R_1 is defined as in claim 23, or a pharmaceutically acceptable salt thereof.

34. (Currently amended) ~~A compound of claim 16~~ An oxycodone prodrug having the following structure



or a pharmaceutically acceptable salt thereof.

35-37. (Canceled)

38. (New) A pharmaceutical formulation comprising at least one of the oxycodone prodrugs of claims 19-34.